Acute myeloid leukemia: open trials in Puerto Rico

10 open trials have a site in Puerto Rico. Registry data; only the trial team decides who can take part.

NCT05554406
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Trial Treatment · Phase 2 · National Cancer Institute (NCI)
San Juan City Hospital, San Juan · Centro Comprensivo de Cancer de UPR, San Juan
Registry updated 2026-11-06
NCT07437950
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Trial Treatment · Phase 2 · National Cancer Institute (NCI)
San Juan City Hospital, San Juan · Centro Comprensivo de Cancer de UPR, San Juan
Registry updated 2026-11-06
NCT06317649
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Trial Treatment · Phase 2 · National Cancer Institute (NCI)
San Juan City Hospital, San Juan · Centro Comprensivo de Cancer de UPR, San Juan
Registry updated 2026-11-04
NCT06917911
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
Trial Treatment · Phase 2 · National Cancer Institute (NCI)
Centro Comprensivo de Cancer de UPR, San Juan · San Juan City Hospital, San Juan
Registry updated 2026-11-04
NCT05564390
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Trial Treatment · Phase 2 · National Cancer Institute (NCI)
Centro Comprensivo de Cancer de UPR, San Juan · San Juan City Hospital, San Juan
Registry updated 2026-11-02
NCT05554393
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Trial Treatment · Phase 2 · National Cancer Institute (NCI)
San Juan City Hospital, San Juan · Centro Comprensivo de Cancer de UPR, San Juan
Registry updated 2026-10-28
NCT06672146
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Trial Treatment · Phase 2 · National Cancer Institute (NCI)
Centro Comprensivo de Cancer de UPR, San Juan · San Juan City Hospital, San Juan
Registry updated 2026-10-27
NCT04065399
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Trial Treatment · Phase 1/2 · Syndax Pharmaceuticals
Hospital Centro Comprensivo de Cancer UPR, San Juan
Registry updated 2026-10-09
NCT04293562
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Trial Treatment · Phase 3 · Children's Oncology Group
University Pediatric Hospital, San Juan
Registry updated 2026-09-17
NCT04726241
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Trial Treatment · Phase 1/2 · PedAL BCU, LLC
HIMA San Pablo Oncologic Hospital, Caguas · University Pediatric Hospital, San Juan
Registry updated 2026-08-25

All Acute myeloid leukemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error